4583 On Other Exchanges
Symbol
Exchange
4583 is not on other exchanges.

chiome bioscience inc (4583) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIOME BIOSCIENCE INC (4583)
\

Related News

No related news articles were found.

chiome bioscience inc (4583) Related Businessweek News

No Related Businessweek News Found

chiome bioscience inc (4583) Details

Chiome Bioscience Inc. engages in the research and development of drug discovery platform technology worldwide. It helps drug discovery companies, such as drug manufacturers and biotech companies to develop antibody drugs through programs based on the autonomously diversifying library system (ADLib system). The ADLib system is a monoclonal antibody generating system that provides various arrays of antibodies in vitro, without using immunization. The company develops the ADLib system to generate therapeutics antibodies; and licenses novel therapeutic antibodies for antigens to pharmaceutical manufactures. Chiome Bioscience Inc. was founded in 2005 and is headquartered in Tokyo, Japan.

Founded in 2005

chiome bioscience inc (4583) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

chiome bioscience inc
Chiome Bioscience Inc. Reports Non-Consolidated Financial Results for the Year Ended Dec. 31, 2017

Chiome Bioscience Inc. reported non-consolidated financial results for the year ended Dec. 31, 2017. For the year, the company reported operating loss of ¥887 million and net loss of ¥882 million or ¥33.48 per share on net sales of ¥259 million against operating loss of ¥1,047 million and net loss of ¥1,491 million or ¥65.91 per share on net sales of ¥252 million for the last year. Negative ROE was 20.3% against 32.9% for the last year. Cash Flow from operating activities was ¥867 million against ¥969 million for the last year. Loss before income taxes was ¥880 million against ¥1,501.3 million for the last year. Purchase of property and equipment was ¥4.975 million against ¥10.455 million for the last year. Purchase of intangible assets was ¥500,000.

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2018

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2018.

Chiome Bioscience Inc., 2017 Earnings Call, Feb 16, 2018

Chiome Bioscience Inc., 2017 Earnings Call, Feb 16, 2018

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4583 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4583.
View Industry Companies
 

Industry Analysis

4583

Industry Average

Valuation 4583 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHIOME BIOSCIENCE INC, please visit www.chiome.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.